News Release

Good Manufacturing Practices Licenses Received

Date: April 9, 2003

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the `Company`) is very pleased to announce that it has received 2 Good Manufacturing Practices (GMP) licenses for Pharmaceutical Products from the State Drug Administration (SDA) of the People`s Republic of China.

The 1st GMP license is for `Small Volume Parenteral Solutions` or solutions for injections. Currently our products including our main platform drugs Tectin(tm) and Tetrodin(tm) are injections. This certificate is valid until April 1, 2008. The 2nd GMP license is the manufacturing of Active Pharmaceutical Ingredients (API), i.e. Tetrodotoxin. This license is valid until April 1, 2004 and validates our current system for extracting from a biological substance a pharmaceutical grade product.

These licenses validate our recent expenditure and plant upgrading and assure our ability to supply our ampoules and vials for our Product Quality to the increasing market demand.

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substances using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Donna Shum, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.